Scienture Holdings, Inc. (SCNX) Income Statement

NASDAQ: SCNXRevenue, profits, margins and EPS over 10 years.

SCNX 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+215.9%
$431,609
2025 · hover or tap a bar for each year
2016: $2.5M (−14.8%)2017: $2.9M (+18.1%)2018: $3.8M (+30.7%)2019: $7.4M (+94.1%)2020: $17.1M (+130.3%)2021: $9.9M (−42.2%)2022: $10.3M (+3.6%)2023: $1.4M (−86.7%)2024: $136,643 (−90.0%)2025: $431,609 (+215.9%)
20162025
Gross profit+5,420.1%
$331,482
2025 · hover or tap a bar for each year
2016: $2.5M (−9.4%)2017: $2.9M (+18.9%)2018: $3.4M (+15.4%)2019: $4.9M (+44.0%)2020: $5.7M (+17.2%)2021: $4.7M (−16.8%)2022: $5.5M (+16.3%)2023: $49,030 (−99.1%)2024: $6,005 (−87.8%)2025: $331,482 (+5,420.1%)
20162025
Operating income
−$16.2M
2025 · hover or tap a bar for each year
2016: −$1.0M2017: $395,0952018: −$87,616 (−122.2%)2019: $125,2242020: −$2.5M (−2,101.7%)2021: −$5.3M2022: −$2.9M2023: −$4.4M2024: −$14.7M2025: −$16.2M
20162025
Net income−557.9%
−$41.5M
2025 · hover or tap a bar for each year
2016: −$2.8M2017: $288,9832018: $9,038 (−96.9%)2019: −$284,428 (−3,247.0%)2020: −$2.5M2021: −$5.3M2022: −$3.5M2023: −$17.8M2024: $9.1M2025: −$41.5M (−557.9%)
20162025
EPS (diluted)−106.6%
−$1.13
2025 · hover or tap a bar for each year
2016: −$6.922017: $0.792018: $0.51 (−35.4%)2019: −$0.67 (−231.4%)2020: −$4.802021: −$9.902022: −$6.152023: −$20.492024: $17.062025: −$1.13 (−106.6%)
20162025
Net profit margin−16,252.7 pts
−9,618.0%
2025 · hover or tap a point for each year
2016: −111.2% (−72.9 pts)2017: 9.9% (+121.1 pts)2018: 0.2% (−9.6 pts)2019: −3.8% (−4.1 pts)2020: −14.8% (−11.0 pts)2021: −53.8% (−38.9 pts)2022: −33.9% (+19.9 pts)2023: −1,308.3% (−1,274.5 pts)2024: 6,634.7% (+7,943.0 pts)2025: −9,618.0% (−16,252.7 pts)
20162025

SCNX revenue and net income

RevenueNet incomeNet margin (right axis)

Where SCNX's revenue goes

2025
Revenue
$431,609100.0%
Cost of revenue
−$100,127−23.2%
Gross profit
$331,48276.8%
Research & development
−$2.0M−453.3%
Sales, general & admin
−$14.5M−3,364.8%
Other operating expenses
−$97,261−22.5%
Operating income
−$16.2M−3,763.8%
Interest & other expense
−$27.3M−6,316.4%
Income taxes
$2.0M462.2%
Net income
−$41.5M−9,618.0%

Each bar shows an amount and its share of revenue. SCNX kept −9,618.0% of revenue as net income.

SCNX profit margins

GrossOperatingNet

SCNX growth rates

to 2025
1 year3 years5 years10 years
Revenue+215.9%−65.2%−52.1%−17.4%
Gross profit+5,420.1%−60.8%−43.4%−19.0%
Operating income————
Net income−557.9%———
EPS (diluted)−106.6%———

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

SCNX quarterly EPS vs estimates

Reported EPSAnalyst estimate

Scienture beat the analyst EPS estimate in 3 of the last 5 quarters. Next report: November 11, 2026 (estimate $-1.50).

SCNX income statement

Scienture Holdings, Inc. annual income statement
2025202420232022202120202019201820172016
Revenue$431,609$136,643$1.4M$10.3M$9.9M$17.1M$7.4M$3.8M$2.9M$2.5M
Cost of revenue$100,127$130,638$1.3M$4.7M$5.1M$11.4M$2.6M$449,049$0$16,362
Gross profit$331,482$6,005$49,030$5.5M$4.7M$5.7M$4.9M$3.4M$2.9M$2.5M
Research & development$2.0M$2.2M$100,280$993,185$899,705$662,726—$949,948$863,324—
Sales, general & admin$14.5M$12.1M$3.4M$6.6M$7.5M$7.5M$4.4M$3.5M$1.4M$3.3M
Total operating expenses$16.6M$14.7M$4.4M$8.4M$10.0M$8.2M$4.7M$3.5M$2.5M$3.5M
Operating income−$16.2M−$14.7M−$4.4M−$2.9M−$5.3M−$2.5M$125,224−$87,616$395,095−$1.0M
Interest income$302,702$135,337$4,198$20,989$0—————
Interest expense$4.1M$1.3M$1.1M$336,206$23,590$29,389$53,227$57,541$157,056$151,500
Income before taxes−$43.5M−$18.8M−$8.5M−$2.4M−$5.3M−$2.5M−$284,428$9,038$288,983−$1.2M
Income taxes−$2.0M−$534,396————————
Net income−$41.5M$9.1M−$17.8M−$3.5M−$5.3M−$2.5M−$284,428$9,038$288,983−$2.8M
EBITDA−$38.9M−$17.4M−$6.3M−$1.9M−$5.2M−$2.4M−$136,470$66,579$446,039−$1.0M
EPS (diluted)−$1.13$17.06−$20.49−$6.15−$9.90−$4.80−$0.67$0.51$0.79−$6.92
Gross margin76.8%4.4%3.6%53.8%48.0%33.3%65.5%88.3%100.0%99.3%
Operating margin−3,763.8%−10,758.7%−322.4%−28.4%−53.5%−14.6%1.7%−2.3%13.5%−40.6%
Net margin−9,618.0%6,634.7%−1,308.3%−33.9%−53.8%−14.8%−3.8%0.2%9.9%−111.2%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SCNX's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

SCNX financial results

In fiscal year 2025 (ended December 31, 2025), Scienture reported revenue of $0.4 million, up 215.9% from the year before. It had a net loss of $41.5 million, a net profit margin of −9,618.0%. Diluted earnings per share came to −$1.13. Over five years revenue grew at an average rate of −52.1% a year.

See the SCNX stock overview for the latest quote and news, or the SCNX chart for price history and technical indicators.

SCNX income statement FAQ

What is Scienture's annual revenue?

Scienture reported total revenue of $0.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 215.9% from $0.1 million the previous year.

Is Scienture profitable?

No. Scienture reported a net loss of $41.5 million in fiscal 2025, a net profit margin of −9,618.0%; its operating margin was −3,763.8%.

What is Scienture's gross margin?

Scienture's gross margin was 76.8% in fiscal 2025: for every $100 of revenue, Scienture kept $77 after the direct cost of its products and services.

How much does Scienture spend on research and development?

Scienture spent $2.0 million on research and development in fiscal 2025, 453.3% of revenue.

How fast is Scienture growing?

Revenue grew −52.1% a year on average over the last five fiscal years, from $17.1 million to $0.4 million.

What are Scienture's earnings per share?

Scienture earned $-1.13 per diluted share in fiscal 2025, compared with $17.06 a year earlier.

When will Scienture report its next earnings?

Scienture is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.

When does Scienture's fiscal year end?

Scienture's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.

Pharmaceutical Retailers income statements